Comparative Pharmacology
Head-to-head clinical analysis: NEXPLANON versus SEASONALE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NEXPLANON versus SEASONALE.
NEXPLANON vs SEASONALE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Progestin-only contraceptive that suppresses ovulation primarily by inhibiting the mid-cycle LH surge. It also thickens cervical mucus, impeding sperm penetration, and alters endometrial lining.
Seasonale is a combination oral contraceptive containing ethinyl estradiol and levonorgestrel. It suppresses gonadotropin release, inhibiting ovulation, and alters cervical mucus to reduce sperm penetration and endometrial lining to reduce implantation.
68 mg subdermal implant inserted in the inner upper arm; provides contraception for up to 3 years.
One tablet (0.03 mg ethinyl estradiol and 0.15 mg levonorgestrel) orally once daily for 84 consecutive days, followed by 7 days of placebo.
None Documented
None Documented
Terminal elimination half-life approximately 25 hours (range 20-30 hours) after removal; steady-state achieved within 3-4 days; clinical effect persists for 3-4 weeks post-removal due to residual subcutaneous depot.
Ethinyl estradiol: terminal half-life 13-27 hours (mean 17 hours); levonorgestrel: terminal half-life 11-45 hours (mean 25 hours). Clinical context: Supports once-daily dosing; steady-state achieved within 5-10 days.
Renal (40-50% as metabolites), fecal (30-40% as metabolites), with <1% unchanged in urine; enterohepatic circulation contributes to prolonged elimination.
Renal excretion of metabolites (approximately 50-60% as glucuronide and sulfate conjugates of ethinyl estradiol and levonorgestrel) and fecal elimination (approximately 40-50%).
Category C
Category C
Contraceptive
Contraceptive, Combination Hormonal